|
 |
| home > pmps > autumn 2002 > packaging and labelling postponement - the antidote to stock keeping unit proliferation |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
With an integrated market and a single European currency, the hope was that business would become simpler and more harmonised across Europe. The reality has been something different - at least in one important part of the business, namely product packaging and labelling. These activities remain as costly and complex as ever at many companies. The situation is particularly acute in highly regulated industries such as pharmaceuticals, consumer/industrial goods and chemicals.
A number of factors are driving this complexity. Foremost among them are country-specific regulations mandating language and product information requirements. For example, the forthcoming seventh amendment to the EU Cosmetic Directive will introduce a number of new requirements for the labelling of cosmetics. One provision would require some of the proposed language combinations, currently provided for by a single stock keeping unit (SKU), to be split into two separate SKUs.
Internal factors play a big part in this complexity as well. Sales and marketing departments, for example, often insist upon country-specific labelling variations to support differentiated pricing. Inefficient product portfolio management is equally problematic, and results in unnecessary variations in the packaging and labelling processes. The cumulative effect of these factors, whether external or internal, is SKU proliferation - a condition that adds cost and complexity to a company's supply chain.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
7th Annual Pharma Packaging and Labelling conference
17 September - 18 October 2008, Barcelona
7th Annual Pharma Packaging and Labelling conference will bring
together experts from leading pharma manufacturers to present case study driven
presentations on critical industry-wide issues.
Attending this event will give you an opportunity to discuss with fellow
packaging and labelling professionals and share your views on these important
matters.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
